Calypte Biomedical Corporation – Employment Agreement (August 14th, 2008)
THIS EMPLOYMENT AGREEMENT (the "Agreement"), dated 11 June 2008, by Calypte Biomedical Corporation, a Delaware corporation ("Calypte") and Mr. Don Taylor (the "Employee"), Basset Shaw, Uxmore Road, Checkendon RG8 0TD, UK.
Calypte Biomedical Corporation – Amendment No. 3 to Secured 8% Convertible Promissory Notes (December 10th, 2007)
THIS AMENDMENT NO. 3 (this "Amendment") to Secured 8% Convertible Promissory Notes, as amended by Amendment No. 2 to Secured 8% Convertible Promissory Notes dated July 3, 2007, and Amendment to Secured 8% Convertible Promissory Notes dated March 21, 2007 (each, a "Note," and collectively, the "Notes"), is made as of December 3, 2007, by and between Calypte Biomedical Corporation, a Delaware corporation (the "Company"), and Marr Technologies BV, a limited liability company established in the Netherlands (the "Investor"). If there is any inconsistency between the terms of this Amendment and any other agreement referenced herein, the terms of this Amendment will govern.
Calypte Biomedical Corporation – Seventh Amendment to 2005 Credit Facility (December 10th, 2007)
THIS SEVENTH AMENDMENT TO 2005 CREDIT FACILITY AGREEMENT (this "Amendment") is made as of December 3, 2007, by and among Calypte Biomedical Corporation, a Delaware corporation ("Issuer"), and Marr Technologies, BV, a limited liability company established in the Netherlands ("Purchaser"). Unless otherwise defined herein, all capitalized terms used herein shall have the meanings given to them in the Credit Facility referred to below.
Calypte Biomedical Corporation – Contract (August 15th, 2006)
Exhibit 99.1 Prepared Remarks of Roger I. Gale and Theodore R. Gwin Calypte Biomedical Corporation Second Quarter 2006 Analyst/Investor Conference Call August 9, 2006 Tim Clemensen - Calypte Biomedical Corporation - Rubenstein IR Good afternoon and welcome to the Calypte Biomedical Second Quarter 2006 Results Conference Call. Joining us today from the Calypte management team are Roger Gale, Chairman and Chief Executive Officer and Ted Gwin, Chief Financial Officer. Management's comments can be accessed via the Internet at the following address www.calypte.com and click on Investors. The conference call will be available for replay through September 8, 2006. By now you should have received a copy of the Company's second quarter 2006 earnings release that was issued last Friday. If you have not, you can view the press release at Calypte's web site at calypte.com or feel free to contact our office at 2
Calypte Biomedical Corporation – Contract (March 30th, 2006)
Exhibit 10.168 Equity Transfer Agreement Chapter 1. Parties Article 1. The Parties to this agreement are as follows: Party A ("Transferor"): Marr Technologies Asia Limited ("Marr") Registered address: Oliaji Trade Center - 1st floor, Victoria Mahe, Seychelles Legal representative: Janak Basnet Position: Director Nationality: Nepali Party B ("Transferee"): Calypte Biomedical Corporation ("Calypte") Registered address: 5 Centerpointe Drive, Suite 400, Lake Oswego, OR 97035 Legal representative: Roger I. Gale Position: President and CEO Nationality: British Chapter 2. Object of the Agreement and the Transfer Thereof Article 2. Party A agrees to transfer fifty-one percent (51%) of the equity interest ("Transfer Equity") of Beijing Marr Bio-Pharmaceutical Manufacturing Co., Ltd. ("the Company") t
Calypte Biomedical Corporation – Contract (January 10th, 2006)
Exhibit 10.167 [CALYPTE BIOMEDICAL CORPORATION] [LETTERHEAD] January 4, 2006 PERSONAL AND CONFIDENTIAL Mr. Roger I. Gale c/o Wavecrest 87 Cheapside London EC2V 6EB United Kingdom Dear Roger: The Compensation Committee of the Board of Directors of Calypte Biomedical Corporation ("Calypte") has approved the following terms of compensation to you for your services as interim chief executive officer of Calypte. The compensation set forth herein relates to your services as interim chief executive officer only and does not include compensation you may receive as a member of the Board of Directors or as Chairman of the Board of Directors. The term of your services commenced as of October 3, 2005. As compensation for your services, you will receive: o During the term you are acting as interim chief executive officer, USD $15,000 per month, payable in equal bi-monthly installments. o
Calypte Biomedical Corporation – Contract (February 10th, 2005)
CONSULTING AGREEMENT AGREEMENT, effective as of the 9th day of February, 2005, between Calypte Biomedical Corporation, a Delaware Corporation (the "Company"), 5000 Hopyard Blvd., Suite 480, Pleasanton, CA 94588, and Roger Gale, c/o Wavecrest, 87 Cheapside, London EC2V 6EB, UK ("Consultant"). WHEREAS, THE Company desires the Consultant to provide consulting services to the Company pursuant hereto and Consultant is agreeable to providing such services. NOW THEREFORE, in consideration of the premises and the mutual promises set forth herein, the parties hereto agree as follows: 1. Consultant shall serve as a consultant to provide the Company strategic consulting and other services including but not limited to the following areas: a) Evaluating its cost structure. b) Reviewing its business operations, finances and organizational structure. 2. Term: The Com